Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVZO-021 in Advanced Solid Tumors
NCT05867251Phase 2Recruiting
- Sponsor
- Avenzo Therapeutics
- Start
- Aug 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ARTS-021 in solid tumor, breast cancer, ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Avenzo Therapeutics. Started Aug 2023; status: recruiting.
02
Drugs
ARTS-021
03
Conditions
solid tumorbreast cancerovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05867251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867251.